Travere Therapeutics Hits New 52-Week High of $55.10, Up 644.7% Year-Over-Year

Travere Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 55.10 on June 17, 2026. This achievement marks a remarkable increase in the stock's performance, reflecting a 644.7% rise over the past year, significantly outpacing the S&P 500's 24.03% performance during the same period. As a small-cap company in the Pharmaceuticals & Biotechnology industry, Travere Therapeutics has a market capitalization of USD 2,514 million. Despite its impressive stock performance, the company remains in a loss-making position, with a negative return on equity of -43.77%. The stock's price-to-book ratio stands at 21.89, indicating a premium valuation relative to its book value. The company's debt-to-equity ratio is slightly negative at -0.05, suggesting a conservative approach to leveraging. With no dividend yield currently offered, Travere Therapeutics continues to focus on its growth trajectory within the competitive pharmaceutical landscape. The recent price movement underscores the stock's dynamic activity and the evolving market conditions surrounding the company.